Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

prescription medicines

- PMLiVE

AZ strengthens Daiichi Sankyo partnership with new ADC deal

Deal for experimental antibody drug conjugate could reach $6bn

- PMLiVE

UK government and GSK/Sanofi sign COVID-19 vaccine supply deal

UK adds to its arsenal of potential vaccine candidates

AstraZeneca AZ

Emergent inks $174m deal with AstraZeneca to manufacture COVID-19 vaccine

Follows initial deal agreed in June

AstraZeneca AZ

AZ/Oxford’s COVID-19 vaccine proves promising in early trials

Vaccine candidate produced robust immune response

- PMLiVE

GSK agrees on 10% equity stake in mRNA specialist CureVac

Equity investment totals £130m with an upfront payment of £104m

- PMLiVE

AstraZeneca’s Farxiga scores another FDA fast-track designation

Company is aiming for approval in prevention indication

AstraZeneca AZ

AstraZeneca’s Brilinta reduces rate of secondary stroke

Drug helps to prevent rate of stroke and death by 17%

- PMLiVE

IFPMA launches AMR Action Fund to tackle antimicrobial resistance

Pharma and health organisations unite to address public health threat

- PMLiVE

GSK signs deal with Medicago for COVID-19 vaccine

Collaboration will utilise GSK’s pandemic adjuvant platform

AstraZeneca AZ

EU gives AZ’s Lynparza green light for BRCA-mutated pancreatic cancer

PARP inhibitor now available for rare, life-threatening disease

- PMLiVE

EMA fast-tracks review of AZ/Daiichi Sankyo’s HER2 drug

Antibody drug conjugate gained approval in US in December

- PMLiVE

Britain closes in on £500m COVID-19 vaccine deal with Sanofi/GSK

Alleged deal could include agreement for 60 million doses

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links